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Abstract
The ABC transporters P-glycoprotein (P-gp, Abcb1) and breast cancer resistance protein (Bcrp, Abcg2) regulate the CNS
disposition of many drugs. The main psychoactive constituent of cannabis D
9-tetrahydrocannabinol (THC) has affinity for P-
gp and Bcrp, however it is unknown whether these transporters modulate the brain accumulation of THC and its functional
effects on the CNS. Here we aim to show that mice devoid of Abcb1 and Abcg2 retain higher brain THC levels and are more
sensitive to cannabinoid-induced hypothermia than wild-type (WT) mice. Abcb1a/b (2/2), Abcg2 (2/2) and wild-type (WT)
mice were injected with THC before brain and blood were collected and THC concentrations determined. Another cohort of
mice was examined for THC-induced hypothermia by measuring rectal body temperature. Brain THC concentrations were
higher in both Abcb1a/b (2/2) and Abcg2 (2/2) mice than WT mice. ABC transporter knockout mice exhibited delayed
elimination of THC from the brain with the effect being more prominent in Abcg2 (2/2) mice. ABC transporter knockout
mice were more sensitive to THC-induced hypothermia compared to WT mice. These results show P-gp and Bcrp prolong
the brain disposition and hypothermic effects of THC and offer a novel mechanism for both genetic vulnerability to the
psychoactive effects of cannabis and drug interactions between CNS therapies and cannabis.
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Introduction
Cannabis is the most widely used illicit drug in the world and
may trigger psychiatric disorders such as psychosis and addiction
in genetically vulnerable individuals [1]. Research identifying the
exact genes that comprise genetic vulnerability to cannabis-
induced brain disorders is in its infancy. A catechol-o-methyl-
transferase gene variant (COMT) increases the risk of developing
schizophrenia in adolescent cannabis users [2,3]. Our own
preclinical research has shown that the schizophrenia susceptibility
gene, neuregulin 1, modulates the neurobehavioural effects of the
main psychoactive constituent of cannabis, D
9-tetrahydrocannab-
inol (THC) [4,5,6,7]. While studies have focused on pharmaco-
dynamic aspects of gene-cannabinoid interactions, here we aim to
explore a mechanism involving adenosine triphosphate (ATP) -
binding cassette (ABC) transporters that might enhance disposition
of THC in the brain.
ABC transporters are a family of drug efflux pumps that utilize
ATP hydrolysis to transport substrates across biological mem-
branes and were originally discovered due to their role in
mediating multidrug resistance (MDR) to anti-cancer drugs [8].
They regulate the disposition of many drugs in tissues because they
are localised in excretory organs such as the liver, intestine and the
blood-brain barrier (BBB) [9,10,11,12]. Two of the most
characterized ABC transporters, P-glycoprotein (P-gp, encoded
by MDR1/ABCB1) and breast cancer resistance protein (Bcrp,
encoded by BCRP/ABCG2), are both found at the apical surface of
capillary endothelial cells that comprise the BBB. P-gp has been
shown to regulate the brain accumulation of various central
nervous system (CNS) drugs including antipsychotics, selective
serotonin reuptake inhibitors, opioids and antiepileptic agents
[13,14,15]. Similarly Bcrp affects brain disposition of drugs [16]
and often cooperates with P-gp to extrude compounds from the
brain because these transporters share overlapping substrate
specificities [17,18,19].
A recent study suggests P-gp regulates the brain disposition of
THC, as an ABCB1 polymorphism was associated with an
increased risk of developing cannabis dependence [20]. In vitro
studies show cannabinoids bind ABC transporters and that THC
stimulates P-gp ATPase activity and inhibits Bcrp
[21,22,23,24,25]. Further, CFI mice naturally deficient in P-gp
expression accumulate higher plasma levels of THC following oral
dosing than wild-type (WT) mice implying that THC is a substrate
of P-gp [26]. However no prior studies have directly shown that P-
gp and Bcrp regulate the brain disposition of THC.
One strategy to examine whether THC is a substrate of P-gp
and Bcrp with implications for its CNS-disposition is to utilize
mice devoid of ABC transporter genes [14,27,28]. Prior studies
have demonstrated that Abcb1a/b (2/2) and Abcg2 (2/2) mice
attain higher brain levels of P-gp and Bcrp substrate drugs [14,19].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35937Using these mice we aim to show that Abcb1a/b (2/2) and Abcg2
(2/2) retain higher brain levels of THC and that this has
functional consequences for CNS-mediated actions of THC.
Results
Higher brain and blood levels of THC in Abcb1a/b (2/2)
and Abcg2 (2/2) mice
Results from brain and blood THC analyses obtained from
WT, Abcb1a/b (2/2) and Abcg2 (2/2) mice are represented in
Figure 1. Both Abcb1a/b (2/2) and Abcg2 (2/2) mice achieved
higher brain concentrations of THC than WT mice when
collapsing all time-points together (Figure 1A) [Mann-Whitney
U test, P=0.0006; P=0.0002 respectively]. The differences in
brain concentrations of THC were evident post-1 h of adminis-
tration with Abcb1a/b (2/2) and Abcg2 (2/2) mice showing
higher brain THC levels than WT at both 2 h (Mann-Whitney U
test, P=0.0065 and P=0.0176 respectively) and 3 h (Mann-
Whitney U test, P=0.0090 and P=0.0143 respectively). Abcg2
(2/2) mice also had significantly higher brain THC concentra-
tions than Abcb1a/b (2/2) mice 3 hours post-administration
(Mann-Whitney U test, P=0.0143). When including all time-
points together in the analysis neither Abcb1a/b (2/2)o rAbcg2
(2/2) mice showed higher blood THC concentrations than WT
(Figure 1B). However, both the Abcb1a/b (2/2) and Abcg2 (2/2)
mice (Mann-Whitney U test P=0.0139; P=0.0143) had signifi-
cantly higher blood THC levels than WT at 3 h.
Brain/blood THC ratios in Abcb1a/b (2/2) and
Abcg2 (2/2) mice
Brain/blood THC concentration ratios for WT, Abcb1a/b (2/2)
and Abcg2 (2/2) mice are shown in Table 1. When including all
time-points neither Abcb1a/b (2/2)o rAbcg2 (2/2) mice displayed
higher brain/blood THC concentration ratios compared to WT
mice (Mann-Whitney U test, Ps.0.05). While not reaching
statistical significance, at the 2 h time-point WT mice retained
only 1.3 times higher brain THC than blood THC concentrations,
whereas Abcb1a/b (2/2) and Abcg2 (2/2) mice attained 4.18 and
6.09 times higher brain THC than blood THC levels respectively
(Mann-Whitney U test, Ps.0.05).
Augmented THC-induced hypothermia in
Abcb1a/b (2/2) and Abcg2 (2/2) mice
Given that both Abcb1a/b (2/2) and Abcg2 (2/2) mice
retained higher concentrations of THC in the brain we proceeded
to test whether this had functional consequences by examining
whether Abcb1a/b (2/2) and Abcg2 (2/2) mice were more
sensitive than WT mice to the hypothermic actions of THC - an
effect mediated by the CNS (see Figure 2). THC exposure in WT
mice significantly reduced body temperature from baseline at
30 min post-injection (Wilcoxon test, P=0.0180) and this
hypothermia disappeared 2–3 h following THC exposure. Abcg2
(2/2) mice had significantly greater THC-induced hypothermia
than WT mice at the 2 and 3 h time-points post-injection (Mann-
Whitney U test, P=0.0452 and P=0.0319 respectively). Abcb1a/b
(2/2) mice had significantly greater hypothermia than WT mice
at 2 h post-injection only (Mann-Whitney U test, P=0.0266).
Discussion
Here we show for the first time that the ABC transporters P-gp
and Bcrp regulate the brain disposition and consequent CNS-
mediated functional effect of the main psychoactive constituent of
cannabis, THC. Both Abcb1a/b (2/2) and Abcg2 (2/2) mice
retained greater brain THC concentrations and were more
sensitive to hypothermia promoted by THC than WT mice. This
appeared to be explained by impaired elimination of the drug from
Figure 1. Abcb1a/b (2/2) and Abcg2 (2/2) mice display higher brain and blood THC levels compared to WT mice. Brain (A) and blood
(B) THC concentrations in WT, Abcb1a/b (2/2) and Abcg2 (2/2) mice at 0.5, 1, 2 and 3 h after acute administration of THC (mean 6 SEM). Abcb1a/b
(2/2)o rAbcg2 (2/2) compared to WT group at specific time-points * P,0.05, ** P,0.01, Abcb1a/b (2/2) compared to Abcg2 (2/2), # P,0.05. For
WT mice n=6 (0.5 h), n=5 (1 h), n=6 (2 h) and n=5 (3 h). For Abcb1a/b (2/2) n=6 (0.5 h), n=5 (1 h), n=6 (2 h) and n=5 (3 h). For Abcg2 (2/2)
n=6 (0.5 h), n=5 (1 h), n=5 (2 h) and n=4 (3 h).
doi:10.1371/journal.pone.0035937.g001
Table 1. Brain/blood THC ratios in Abcb1a/b (2/2) and Abcg2
(2/2) mice compared to WT mice.
Brain/blood THC ratios
Time (h) 0.5 1 2 3
WT 1.260.52 2.1160.24 1.3060.35 1.6760.44
Abcb1a/b (2/2) 1.8060.37 3.2060.93 4.1861.41 1.5460.45
Abcg2 (2/2) 3.3361.78 1.9360.50 6.0961.90 2.4060.35
The ratio of brain to blood THC concentrations in WT, Abcb1a/b (2/2) and
Abcg2 (2/2) mice from data collected at 0.5, 1, 2 and 3 h after an acute
administration of THC (mean 6 SEM).
doi:10.1371/journal.pone.0035937.t001
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concentrations over time, whereas Abcb1a/b (2/2)a n dAbcg2
(2/2) mice maintained higher THC concentrations that were first
evidentinthebrainat2 hpost-injectionbeforeitwasobservedinthe
blood at 3 h. The time-frame of enhanced brain THC concentra-
tions in Abcb1a/b (2/2)a n dAbcg2 (2/2) mice mirrored that
observed for THC-induced hypothermia– an effect mediated by the
CNS.
Our results accord with prior in vitro and in vivo evidence
indicating THC is a substrate of P-gp. THC was first shown to
have affinity for P-gp as it weakly stimulated human P-gp-
dependent ATPase activity [25]. Bonhomme-Faivre et al. (2008)
then demonstrated THC is a P-gp substrate by showing that CFI
mice, which are naturally deficient in Abcb1a, attain higher plasma
levels of THC than WT mice following a 25 mg/kg oral THC
dose [26]. Our results extend this research by showing P-gp
regulates brain disposition of THC. Further, we provide first
evidence that THC is a substrate of Bcrp and that this transporter
regulates brain and blood levels of THC. This finding is consistent
with our prior in vitro evidence showing THC inhibits Bcrp [22]
and suggests THC-induced enhancement of mitoxantrone accu-
mulation in Bcrp-overexpressing cells occurs via competitive
modulation of Bcrp transport.
Our results highlight that THC is a dual substrate for P-gp and
Bcrp which is not surprising given the considerable overlap in the
substrate specificities of P-gp and Bcrp and that many drugs are
transported by both these efflux proteins [17,18,19,32]. THC
appears a better substrate for Bcrp than P-gp because Abcg2 (2/2)
mice retained higher levels of THC than Abcb1a/b (2/2) mice in
the brain at 3 h post-administration. This is at odds with findings
that P-gp has approximately 5-fold higher expression in murine
brain vascular endothelial cells than Bcrp [33,34]. However, our
laboratory has shown that THC inhibits Bcrp but not P-gp
because THC increases accumulation of the Bcrp substrate
mitoxantrone but not the P-gp substrate rhodamine 123 in cells
selectively expressing these respective transporters [22,23]. Taken
together, our results imply THC may have significantly lower
affinity for P-gp than Bcrp.
Our results suggest that P-gp and Bcrp expressed on endothelial
cells that comprise the BBB assist in the active transport of THC
from inside the brain back into the peripheral blood supply.
Abcb1a/b (2/2) and Abcg2 (2/2) mice, without these transport-
ers, display delayed brain elimination of THC leading to the
accumulation of this psychoactive constituent of cannabis in the
CNS. This implies that Abcb1a/b (2/2) and Abcg2 (2/2) mice
could also be more sensitive to CNS-mediated functional effects of
THC. It is well established that THC promotes hypothermia
through its action on the CNS largely by affecting thermoregu-
latory neurons in the hypothalamus [35]. For example, a classic
study by Fitton and Pertwee (1982) demonstrated that intracer-
ebroventricular and intrahypothalamic injections of THC pro-
moted reductions in rectal body temperature in mice [36]. Here
we show that mice devoid of P-gp or Brcp are more sensitive to
hypothermia promoted by THC – a likely functional consequence
of enhanced THC concentrations in the brain affecting thermo-
regulatory neurons in these mice.
Our results offer an additional pharmacokinetic mechanism for
interactions between the approximately 80 different cannabinoid
constituents found in the cannabis plant. Interaction between
THC and another plant-derived cannabinoid constituent canna-
bidiol (CBD) is of particular interest as CBD modulates the actions
of THC [31,37,38,39,40,41]. Indeed this was part of the rationale
behind the development of SativexH, a cannabinoid formulation
containing a 1.07:1 THC : CBD dose, approved for use in various
countries for the treatment of spasticity associated with multiple
sclerosis. CBD’s modulation of THC effects might be partly
explained by pharmacokinetic mechanisms because CBD increas-
es the brain levels of THC and accentuates some of its
neurobehavioural effects [31,37,42]. Our present findings showing
THC is a substrate of P-gp and Bcrp, combined with prior
research indicating CBD inhibits both P-gp and Bcrp [23,25],
highlights a novel ABC transporter-mediated mechanism whereby
CBD might inhibit the transport of THC from the brain
parenchyma back into the blood.
Cannabis-drug interactions should also be considered in future
research as substrates for P-gp and Bcrp include several CNS drugs
that might be co-administered with cannabis such as anticonvul-
sants, antidepressants andantipsychotics [14,43,44,45,46,47,48,49].
This may be particularly problematic for antipsychotic treatment as
there are higher rates of cannabis use in schizophrenia patients than
the general population and cannabis use is associated with poor
antipsychotic treatment outcomes [50,51,52]. THC behaving as a
competitive substrate for P-gp might increase the brain and blood
concentrations of P-gp substrate antipsychotic drugs such as
risperidone and olanzapine [14,48,53] and increase dose-related
side-effects of these drugs. Alternatively, antipsychotic drugs by
inhibiting P-gp and Bcrp [54] might increase CNS accumulation of
THC and increase psychotic reactions and relapse in these patients.
The present findings raise the question of whether ABCB1 and
ABCG2 polymorphisms might explain genetic susceptibility to
cannabis-induced psychosis or the adverse psychoactive effects of
this drug (e.g. addiction, anxiety and cognitive impairment) by
altering the brain disposition of THC. This would provide a
pharmacokinetic source of interindividual variability in response to
cannabis use in addition to other genes that modulate the
pharmacodynamic actions of the drug [2,4,5,6]. Thus far, to the
best of our knowledge, only one human study has addressed
whether single nucleotide polymorphisms (SNPs) in ABC trans-
porter genes confers greater vulnerability to CNS disorders. This
study showed that the ABCB1 variant C3435T (CC genotype)
Figure 2. Greater THC-induced hypothermia in Abcb1a/b (2/2)
and Abcg2 (2/2) mice compared to WT mice. THC-induced
hypothermia in WT, Abcb1a/b (2/2) and Abcg2 (2/2) mice at 0.5, 2 and
3 h post-THC injection. Data expressed as a change from baseline (pre-
THC injection) rectal body temperature reading in these mice at the
various time-points (mean 6 SEM). Abcb1a/b (2/2)o rAbcg2 (2/2)
compared to WT group at specific time-points *P ,0.05, baseline versus
post-THC injection body temperature in WT mice # P,0.05. For WT
mice n=7, Abcb1a/b (2/2) n=6 and Abcg2 (2/2)n=6 .
doi:10.1371/journal.pone.0035937.g002
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was more prevalent in individuals dependent on cannabis than
controls [20]. The CC genotype has been associated with
increased expression of P-gp, whereas the TT genotype decreased
P-gp expression [55]. Therefore, dependent on genotype the SNP
C3435T might decrease or increase THC brain levels and on one
hand increase the propensity of individuals for cannabis
dependence (CC genotype) or increase the risk of developing
cannabis-induced psychosis (TT genotype). Our findings reinforce
the need for future studies to more closely examine the relationship
between SNPs in ABCB1 and ABCG2 and cannabis-related
psychiatric problems such as addiction, schizophrenia and panic
disorder.
In conclusion our results show that the main psychoactive
constituent of cannabis THC is a substrate for the ABC
transporters P-gp and Bcrp. Abcb1a/b (2/2) and Abcg2 (2/2)
mice attained higher brain THC concentrations and were more
sensitive to the CNS-mediated hypothermic effects of THC than
WT mice. These results provide a novel mechanism for genetic
vulnerability to the psychoactive effects of cannabis, the most
widely used illicit drug in the world. Further they highlight a novel
mechanism for drug interactions between cannabis use and CNS
drugs that are substrates for the ABC transporters P-gp and Bcrp.
Materials and Methods
Animals
All Experiments were approved by the University of Sydney
Animal Ethics Committee in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes. Age-
matched female Abcb1a/b (2/2), Abcg2 (2/2) and wild-type
(WT, FVB background strain) mice were used in this study.
Abcb1a/b (2/2) and Abcg2 (2/2) mice were purchased from
Taconic farms (New York, USA) and were developed by Professor
Alfred Schinkel and colleagues at the Netherlands Cancer
Institute, Amsterdam (see [27,28] for the initial characterisation
of these animals). Female mice were used to allow comparison of
our data with a prior study that assessed the disposition of
numerous CNS drugs in female WT and Abcb1a/b (2/2) mice
[14]. Following shipment of founder mice to Australia from the
US all mice genotypes were bred in-house and the offspring were
used for experimentation following rearing under identical
conditions. Mice were 2–3 months old for our first study assessing
the brain and blood concentrations of THC and 4.5 months old
for the second study examining THC-induced hypothermia. All
mice were group-housed with 4–6 mice per cage in a temperature
and humidity controlled room and maintained on a reverse 12-h
light/12-h dark cycle. Experimental sessions took place during the
dark cycle. Mice had ad libitum access to water and rodent lab
chow.
Drug treatment
D
9-Tetrahydrocannabinol (THC Pharm GmbH, Frankfurt) was
dissolved in absolute ethanol before being added to an equal
amount of Tween 80 and diluted in 0.9% saline to give a final
stock of ethanol/Tween 80/saline (1:1:18). All drugs were freshly
prepared before use at an injection volume of 1 ml/kg. THC was
administered intraperitoneally (i.p.) at a dose of 3 mg/kg for the
measurement of THC concentration in brain and blood. At 0.5, 1,
2 and 3 h post-THC injections all mice (Abcb1a/b (2/2), Abcg2
(2/2) and WT animals, n=5–6 per group) were anaesthetised
with isoflurane and blood was collected via cardiac puncture
before brains were extracted and snap frozen in liquid nitrogen.
To avoid coagulation blood was stored in EDTA tubes. Both brain
and blood were stored at 220uC prior to gas chromatography
mass spectrometry (GC-MS) analysis. For the body temperature
study mice (n=6–7 per group) were first tested for baseline rectal
body temperature as previously described (Boucher et al, 2011b).
All mice were then administered an i.p. injection of 10 mg/kg
THC before rectal body temperature measurements at 30 min,
2 h and 3 h post-injection were taken. The higher 10 mg/kg dose
of THC was administered in this study as, unlike 3 mg/kg THC,
this dose significantly reduced body temperature in WT mice,
allowing observation of any potentiation of this effect in Abcb1a/b
(2/2) and Abcg2 (2/2) mice.
GC-MS analysis of THC in biological matrices
The methods used for determining brain and blood THC
concentrations were as described previously [29,30,31]. Briefly for
blood THC analysis, a total of 50 ml of (deuterated) D3-THC
(0.25 mg/L) internal standard solution was added to each 0.5 ml
sample of whole blood. Acetate buffer was added (pH 4.0) to THC
and was extracted with 1-chlorobutane solvent. Calibration
standards were prepared by spiking drug-free sheep blood at
concentrations of 1.25–100 ng/ml for THC. The standards were
vortexed and treated identically to other blood samples. Following
extraction and complete drying under a nitrogen gas stream, the
samples underwent derivatization of the polar functional groups
(COOH, OH) with bis(trimethylsilyl)trifluroacetamide (BSTFA).
The limit of quantification (LOQ) for the blood analysis was
1.25 ng/ml. For brain THC analysis, brains were dissected in half
in the sagittal plane and each hemisphere was weighed. A single
hemisphere was then homogenized in 0.9% saline at a 1:2 ratio
(w/v). A total of 50 ml of (deuterated) D3-THC (0.25 mg/L)
internal standard solution, 2 ml of 0.2 M sodium hydroxide
(pH 13) and 3 ml of acetonitrile were added to each 0.5 ml sample
of homogenized brain samples. Calibration standards were
prepared by spiking drug-free mouse brains at concentrations of
5–200 ng/g for THC. They were then completely dried under
nitrogen gas stream and underwent identical extraction and
derivatization as blood samples, as described above (LOQ=5 ng/
g for the brain analysis). All quantification was performed by GC-
MS (Shimadzu 2010Plus system) using electron impact ionization
in selective ion mode.
Data analysis
All statistical analyses were performed using StatView 5.01 (SAS
Institute Inc. Cary, NC, USA). Comparisons were made between
Abcb1a/b (2/2)o rAbcg2 (2/2) mice versus WT from time-point
data collapsed together or analysed separately using the non-
parametric Mann-Whitney U test. A Wilcoxon test was used to
demonstrate that THC promoted significant hypothermia in WT
mice by comparing the various time-points to baseline (the pre-
THC injection body temperature). Differences were deemed
significant when P,0.05.
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